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This work describes the integration of expanded bed adsorption (EBA) and adsorptive protein refolding operations used to
recover puriﬁed and biologically active human basic ﬁbroblast growth factor from inclusion bodies expressed in E. coli. Insoluble
overexpressed human basic ﬁbroblast growth factor has been puriﬁed on CM Hyper Z matrix by expanded bed adsorption
after isolation and solubilization in 8M urea. The adsorption was made in expanded bed without clariﬁcation steps such as
centrifugation. Column refolding was done by elimination of urea and elution with NaCl. The human basic ﬁbroblast growth
factor was obtained as a highly puriﬁed soluble monomer form with similar behavior in circular dichroism and ﬂuorescence
spectroscopyasnativeprotein.Atotalof92.52%oftheavailablehumanbasicﬁbroblastgrowthfactorwasrecoveredasbiologically
active and puriﬁed protein using the mentioned puriﬁcation and refolding process. This resulted in the ﬁrst procedure describing
high-throughput puriﬁcation and refolding of human basic ﬁbroblast growth factor in one step and is likely to have the greatest
beneﬁt for proteins that tend to aggregate when refolded by dilution.
1.Introduction
Production of therapeutic proteins in inclusion bodies is
useful due to the eﬃcacy of insoluble expression such as
high product yield and protection against degradation by
proteases[1].Therecoveryofbiologicallyactiveproteinfrom
such inclusion bodies requires refolding protocols.
In general, the methods used for inclusion body solubi-
lizationresultinasolubleproteinthatisbiologicallyinactive.
The solublized proteins do not have native conformation
and must be transferred into conditions that allow the
formation of the native structure. During this period, the
correctfoldingpathwaycompetes,oftenindisadvantagewith
misfolding and aggregation of the target protein. Protein
refolding involves intramolecular interactions and follows
ﬁrst-order kinetics [2].
Refolding yields commonly decrease with increasing
initialconcentrationsoftheunfoldedproteinindependentof
the refolding method applied [3]. Aggregates are formed by
nonnative intramolecular hydrophobic interactions between
protein folding intermediates, which have not yet buried
their hydrophobic amino acid stretches. Therefore, pre-
vention of hydrophobic intermolecular interaction during
the ﬁrst steps of refolding is crucial to allow successful
renaturation at high protein concentrations [4].
Av e r ye ﬃcient strategy to prevent aggregation is to
minimize the risk of intermolecular interactions by adsorb-
ing the denatured protein molecules to a solid support,
thus, eﬀectively separating the individual protein molecules
from each other during refolding. The ﬁrst studies on the
refolding of denatured proteins after adsorption to a solid
matrix surface were carried out many years ago. Thus,
Epstein and Anﬁnsen [5] adsorbed trypsin and ribonuclease
to carboxymethyl cellulose for the purpose of studying
the reversible reduction of their disulﬁde bonds. Studies
on the refolding of chymotrypsinogen and trypsin after
covalent attachment to agarose gel have been performed [6],
resulting in 50–70% refolding yield. In 1979, Mozhaev et
al. [7] covalently immobilized trypsin for the same reason.
Following the development of new protein adsorbent media
during the last couple of decades, various chromatographic
methods have been developed to improve refolding yield.2 Biotechnology Research International
Noncovalent (reversible) adsorption of denatured proteins
to ion-exchange media was used by Creighton [8] for the
purpose of refolding.
The need to use large quantities of hbFGF in formulation
study in our lab and its high market cost led us to develop its
refolding and puriﬁcation on a large scale.
Heparin aﬃnity chromatography is widely utilized for
the puriﬁcation of hbFGF but it has not been possible so
far to obtain homogeneous protein preparations in a single-
step process. Heparin aﬃnity chromatography is commonly
combined with a cation-exchange step, maybe followed from
subsequent puriﬁcation steps, such as copper chelate or
hydrophobic interaction or gel permeation chromatography
[9, 10].
These traditional techniques are limited with recom-
binant proteins by intrinsic problem of aggregation [11].
Indeed, most of the recombinant proteins are overexpressed
asinsoluble inclusion bodies orsoluble smallaggregates.The
challenge is to convert the inactive and insoluble inclusion
bodies and small protein aggregates into soluble, correctly
folded biologically active products [12]. Mannen et al.
[13] showed for the ﬁrst time an expanded bed protein
refolding using a solid phase artiﬁcial chaperone. They used
the artiﬁcial chaperone-assisted refolding method and the
expanded bed technique providing a novel industrial scale
protein refolding system. Cho et al. [11] have also proposed
an expanded bed adsorption-mediated refolding process of
a fusion protein. Exploiting the advantages of expanded
bed adsorption chromatography, which is an alternative
to traditional clariﬁcation and the ﬁrst chromatography
step [14–16], they could provide a higher yield with much
less aggregation and, thus, reducing the number of the
renaturation process steps.
The recombinant hbFGF has been overexpressed as
inclusion bodies to increase the quantity of recovered and
to facilitate puriﬁcation. The cell homogenate including
inclusion bodies and small soluble aggregates was dissolved
by urea and then the unfolded recombinant hbFGF was
allowed to adsorb on the chromatographic support. Here,
on-column puriﬁcation and refolding procedure was based
on an ion exchange bed technology and was done in one
step. The incentive of this approach was to obtain a one
step puriﬁcation of high quantity of hbFGF suitable for
automation.
2.MaterialsandMethods
2.1. hbFGF Expression and Extraction. Cloning and expres-
sion of rhbFGF was described by Alibolandi et al. [17].
Brieﬂy, the cell pellets of 1LLB culture of induced transfor-
mants were collected and resuspended in 30mL cold PBS,
pH 7.0. Then, cells were lysed by six passes through high-
pressure homogenizer (APV Manton Gaulin).
2.2.SolubilizationofInclusionBodies. Thehomogenate(con-
taining soluble and insoluble proteins) was diluted with
270mL of 8M urea, PBS pH 7.0 and agitated 8h at 10◦C.
Then, the homogenate was directly used for expanded bed
cation exchange adsorption.
2.3. Chromatographic Procedure
2.3.1. Study Degree of Expansion. Firstly, expanded bed ad-
sorption of two matrices (CM sepharose Streamline and CM
Hyper Z) has been compared. Two buﬀers were evaluated,
PBS, pH 7.0 buﬀer and 8M urea, PBS, pH 7.0 buﬀer. The
ﬂow rate was also compared for twofold degree of expansion.
The degree of expansion was calculated from the ratio of
expanded bed height (L) to sedimented bed height (L0). To
studytheexpansionversusﬂowrate,incrementsof1mL/min
of the ﬂow rate were used from 1mL/min until the ﬂow
rate necessary to obtain a twofold degree of expansion.
In addition, the inﬂuence of high concentrations of urea
and sample on the expansion degree of both matrices was
studied. The matrix allowing the higher ﬂow rate was chosen
for the subsequent puriﬁcation step.
2.3.2. Puriﬁcation of Insoluble hbFGF. Cation exchange ex-
panded bed adsorption was performed with CM Hyper Z
(60mL, 10.4cm sedimented gel) packed in the Streamline 25
column. The column was linked to a Biopilot workstation
(Amersham Pharmacia Biotech). Equilibration/expansion
was performed with 8M urea, PBS, pH 7.0 buﬀer at
40mL/min to obtain a twofold degree of expansion. The
homogenate was applied at 40mL/min, followed by washing
with the equilibration buﬀer until UV baseline was reached.
Then, the pump was turned oﬀ and the bed sedimented.
Next, the adaptor was moved down towards the sedimented
bed surface. After a run of two volumes (sedimented gel)
of equilibration buﬀer, refolding was performed with 10
column volumes of PBS, pH 7.0 buﬀer at a ﬂow velocity of
40mL/min using a downward ﬂow in the sedimented bed
mode.Then,elutionwasperformedintwosteps,0.6MNaCl,
PBS pH 7.0 for the elution of hbFGF and 1M NaCl, PBS, pH
7 for the elution of contaminants and run at 40mL/min.
2.4. Analytical Procedures
2.4.1. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electro-
phoresis and Immunoblot Analysis. Analysis of the fractions
containing hbFGF was performed by electrophoresis on 12%
SDS-polyacrylamide gels under reducing conditions accord-
ing to Laemmli method [18].
The concentration of hbFGF was calculated by deter-
mining the total protein concentration using the Bradford
method [19] and by measuring the percentage of hbFGF by
gel scanning (Image Station 440 CF, Kodak, Rochester, NY,
USA). In addition, the precise amount of hbFGF in fractions
was measured by ELISA kit (R&D, USA).
Western blotting analysis was also applied to detect the
hbFGF in all fractions. All samples were size fractionized
by 12% SDS-PAGE and then transferred to a 0.2µm
pore size nitrocellulose membrane (Schleicher & Schuell,
USA). Rabbit anti-hbFGF anti serum (Sigma, USA) and
horseradish peroxidase conjugated goat-antirabbit antibody
(Sigma, USA) were used as primary and secondary antibody.
The immunoreactions were visualized using 0.5mg/mL
diaminobenzidine HCl (Merck, USA) and 0.01% H2O2
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Figure 1: Inﬂuence of ﬂuid on expansion degree with CM
sepharose and CM hyper Z matrices. Column 1: PBS pH 7; column





































Figure 2: Puriﬁcation of insoluble hbFGF with cation exchange
expanded bed adsorption. Column: CM Hyper Z (60mL of gel).
Sample: unclariﬁed cell lysate in 8M urea, PBS pH 7. Equilibration
buﬀer: 8M urea, PBS pH 7. Refolding buﬀer: PBS pH 7. Elution
buﬀer: 0.2–2M NaCl, 20mM sodium bicarbonate pH 9. Detection
at 280nm; ﬂow rate: 40mL/min. Flow through: no retained
fraction; peak 1: 0.4MNaCl eluted fraction; peak 2: 0.8M NaCl
eluted fraction.
2.4.2.CircularDichroism(CD). CDspectroscopywasusedto
determine the refolded protein secondary and tertiary struc-
tures using JASCO J715 spectropolarimeter and a quartz
cuvette of 0.1cm path length. The protein concentration of
about 0.5mg/mL was used for each CD measurement. The
CD spectra were corrected for buﬀer contributions.
2.4.3. Fluorescence Spectroscopy. Determination of protein
ﬂuorescence spectrum was performed with a Hitachi F-
4010 ﬂuorescence spectrophotometer using a quartz cuvette
with 1cm path length. Excitation and emission slits were
set as 10nm. Fluorescence spectra were then recorded with
an excitation of 295nm and recording the emission spectra
from 200 to 500nm. The samples were incubated for 3h at
room temperature before ﬂuorescence measurements were
recorded.
3. Results and Discussion
3.1. Comparison of Matrices. Before puriﬁcation, expanded
bed adsorption of two matrices has been compared: CM
sepharose and CM Hyper Z Streamline. Two buﬀers were
investigated, PBS, pH 7.0 buﬀer and 8M urea, PBS, pH 7.0
buﬀer. The ﬂow rate was measured for twofold degree of
expansion.
For a twofold degree of expansion with PBS pH 7, the
CM Hyper Z matrix allowed a 40mL/min ﬂow rate which is
twice that of CM sepharose streamline. Figure 1 shows that
8M urea had less eﬀect on CM Hyper Z than CM sepharose
Streamline. The inﬂuence was similar with cellular protein
extract in presence of 8M urea. Therefore, for puriﬁcation
we employed the CM Hyper Z matrix, which allowed a high
ﬂow rate and gave suitable performance in the presence of
8M urea. Moreover, in a previous study, it was showed that
CM sepharose matrix was eﬃcient to purify soluble hbFGF
[17].
Equilibration/expansion was performed with PBS, pH
7.0 buﬀer at 40mL/min upward ﬂow to obtained twofold
degree of expansion. Then, equilibration was performed
with 8M urea, PBS pH 7.0 buﬀer, giving a 2.3-fold degree
of expansion. The inclusion bodies solubilized in 8M urea
(300mL) were applied at 40mL/min and gave a 2.9-fold
degree of expansion.
3.2. Puriﬁcation Step and Analysis of Puriﬁed Refolded hbFGF.
Injection of the sample was followed by washing with 8M
urea, PBS pH 7 buﬀer until UV baseline was reached. Then,
the gel bed was sedimented and a run of two volumes
(sedimentedgel)ofequilibrationbuﬀerwasperformed.Urea
was eliminated with 10 column volumes of PBS, pH 7.0
buﬀer at a ﬂow rate of 40mL/min using a downward ﬂow
in the sedimented bed mode.
Next, the elution was performed, 0.4MNaCl, PBS pH
7.0 for the elution of hbFGF and 0.8M NaCl, PBS pH 7
for the elution of contaminants and was run at 40mL/min
(Figure 2). All fractions were analyzed by SDS-page. The
puriﬁcation results are shown in Table 1. The cell lysate
containing 378mg of target protein was applied onto the
column, 664.3mg proteins passed into the ﬂow through,
and the hbFGF estimated by ELISA was about 23.3mg.
Peak 1 contains 349.72mg hbFGF with 92.52% of recovery.
The recovery and puriﬁcation value are higher than those
obtained in cation exchange puriﬁcation of soluble hbFGF
[17].
However, puriﬁcation with heparin aﬃnity required an
additional step to obtain a single band on SDS-PAGE [20].
The production of hbFGF as inclusion bodies allowed us to
reduce the volume culture for the same quantity of protein
and then the time of process. Besides the reduction of the
number of puriﬁcation steps, fast removal of proteolytic
enzymes and a shortening of the total process time may help
to prevent losses in mass and quality of recombinant hbFGF
due to degradation and precipitation.
Moreover, the use of cation exchange using CM hyper
Z allowed us to avoid further step for puriﬁcation. All







Figure 3: (a) 12% SDS-PAGE analysis of fractions from puriﬁcation of hbFGF. M: Molecular weight marker; lane 1: cell lysate in 8M urea,
PBS pH 7; lane 2: ﬂow through; lane 3: peak 1; lane 4: peak 2. (B) Western blotting of cell lysate and fractions from puriﬁcation of hbFGF.

























































Figure 4: Circular dichroism (CD) spectra of refolded and native hbFGF (a) far-UV spectra for native and refolded hbFGF; (b) near-UV
CD spectra for native and refolded hbFGF.
containing the ﬂow through shows a low level of hbFGF. It
seems that this hbFGF corresponds to insuﬃcient refolded
hbFGF. Indeed, without urea treatment, all the hbFGF
would have passed in the ﬂow through (data not shown).
The native hbFGF from previous puriﬁcation is used as
reference native hbFGF [21]. The molecular mass of refolded
hbFGF seemed to correspond to that of the native hbFGF.
The folding of refolded hbFGF obtained was evaluated by
ﬂuorescence spectroscopy and circular dichroism analysis.
Thesamespectralpropertieswereobtainedbetweenrefolded
andnative hbFGF (Figure 4). Quantitative analysisof the CD
spectra also indicates that refolded hbFGF is predominantly
in beta sheet and other conformations with very little alpha-
helix fraction. These results are in agreement with earlier
observations [22].
It is well established that ﬂuorescence intensity obtained
at an excitation wavelength of 295nm correlates with the
exposure of hydrophobic tryptophan residues on the surface
of the polypeptide [23] and hence the extent of protein
unfolding. hbFGF carrys 8 tryptophan residues [24]. Fluo-
rescence emission of refolded hbFGF exhibited an emission
characteristic that was comparable to native hbFGF. Here,
ﬂuorescence emission of puriﬁed refolded hbFGF exhibited
a very low emission characteristic that was comparable to
native hbFGF (Figure 5).
Obtained results from this study indicate the good
performance of this technique in puriﬁcation and refolding
of hbFGF.
It has been noted that high expanded bed adsorption is
also eﬃcient in recovering active proteins from the unclari-
ﬁed cell culture [25–29].
This technique was applied to puriﬁed proteins from
diﬀerent sources like yeast [30], bacterial cells [31, 32], and
cell cultures [33, 34].
On the other hand, expanded bed adsorption was found
an easy technique to scale-up and automation due to the
reduction of the number of puriﬁcation steps [35].
Here, high density of CM Hyper Z beads allows eﬃcient
processing of cell lysate at very high viscosity (urea 8M)Biotechnology Research International 5
Table 1: Puriﬁcation of hbFGF with the CM hyper Z matrix.
Volume Protein Total protein hbFGF Total hbFGF Recovery Puriﬁcation fold
(mL) (mg/mL) (mg) (mg/mL) (mg) %
Denatured cell lysate 300 4.2 1260 1.26 378
Flow through 910 0.73 664.3 0.02 23.3 6.16 0.116
Peak 1 183 2 366 1.91 349.72 92.52 3.51
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Figure5:FluorescencespectraproﬁleofrefoldedandnativehbFGF.
and high ﬂow rate (40mL/min). Insoluble and soluble
(monomer and small aggregates) hbFGF could be puriﬁed
after solubilization in 8M urea and adsorption in expanded
bed mode to avoid centrifugation. After elimination of urea
on the column and elution with NaCl, the hbFGF was
obtained as a highly puriﬁed soluble form with similar
behavior in ﬂuorescence spectroscopy, circular dichroism,
and electrophoresis as native hbFGF. The results of one-step
protein puriﬁcation and on-column refolding of hbFGF with
cationexchangeexpandedbedchromatographydemonstrate
that it is a promising process allowing automation.
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